 What's in store for biotech in 2024? Perhaps a lot of good! Analysts have said that the 2023 year-end spurt of biopharma mergers and acquisitions bodes well for the sector this year. As biotech potentially stages a big comeback, one little-known NYSE-traded company looks well-positioned to be a market disruptor with nontoxic, effective antiviral therapies based on patented nanomedicine technology. The company is a global leader in the application of nanomedicine technologies to the safe and effective treatment of viruses and their variants INCLUDING drugs against Covid-19, RSV, and other respiratory viruses! What's the deal with NANOVIRICIDES? They are better because they destroy viruses and their variants without relying on the patient's immune system, thereby making them effective for populations that include geriatric and pediatric patients. Antibodies only bind by two points to the virus, and destruction of the complex requires effective immune function, which is not the case in sick patients. Vaccines only train the body to produce antibodies against the virus in the vaccine. Antibodies and vaccines are easily overcome by viruses by mutating in the field, hence the need for annual influenza vaccine updates. ANTIBODIES AND VACCINES ARE OUTDATED: This underfollowed company has a more innovative approach that works even when viruses mutate!!! This message is a PAID ADVERTISEMENT for NanoViricides, Inc. (NYSE American: NNVC) from Interactive Offers. StockEarnings, Inc receives a fixed fee for each subscriber that clicks on a link in this email, totaling up to $1500. Other than the compensation received for this advertisement sent to subscribers, StockEarnings and its principals are not affiliated with either NanoViricides, Inc. (NYSE American: NNVC) or Interactive Offers. StockEarnings and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither StockEarnings nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from StockEarnings to buy or sell any security. StockEarnings has not evaluated the accuracy of any claims made in this advertisement. StockEarnings recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results. Please see the disclaimer regarding NanoViricides, Inc. (NYSE American: NNVC) on Small Caps Daily website for additional information about the relationship between Interactive Offers and NanoViricides, Inc. (NYSE American: NNVC). Your privacy is very important to us, if you wish to be excluded from future notices, do not reply to this message. Instead, please click Unsubscribe. StockEarnings, Inc |
No comments:
Post a Comment